Intratumoral Cancer Therapies Market: Current Analysis and Forecast (2023-2030)

The Intratumoral cancer therapies market was valued at USD 151.5 million in 2022 & is expected to grow at a CAGR of 9.9% from 2023-2030.Intratumoral cancer therapies are a type of cancer treatment that involves delivering therapeutic agents directly into the tumour site. Unlike systemic treatments, which circulate throughout the entire body, intratumoral therapies target cancer cells within the tumour while minimizing exposure to healthy tissues. Growing advancements in immunotherapy, including immune checkpoint inhibitors, CAR-T cell therapies, and oncolytic viruses, are driving interest in intratumoral applications. These therapies stimulate the body’s immune response to target and destroy cancer cells directly within the tumour site.For instance, in February 2021, the FDA approved Merck’s Keytruda (pembrolizumab) for the treatment of high-risk, non-muscle invasive bladder cancer unresponsive to BCG therapy. This approval highlights the potential of immunotherapies in intratumoral applications. Furthermore, the trend toward personalized medicine is driving the development of intratumoral therapies tailored to individual patients’ genetic profiles and tumour characteristics. This approach improves treatment effectiveness and reduces side effects.

Some of the major players operating in the market are AstraZeneca, Amgen Inc., Eli Lilly and Company, AbbVie Inc., F. Hoffmann-La Roche Ltd, Novartis AG, Merck & Co., Inc, Bayer AG, Pfizer Inc., Bristol-Myers Squibb Co. Several M&As along with partnerships have been undertaken by these players to facilitate customers with hi-tech and innovative products/technologies.

Insights Presented in the Report

“Amongst Technology, the monoclonal antibodies segment held a significant share of the market in 2022.”

Based on the technology, the market has been categorized into monoclonal antibodies, cell and gene therapies, cytokines, and others. Among them, the monoclonal antibodies segment is expected to grow at a higher CAGR in the market due to their potential to target specific cancer cells, trigger immune responses, and minimize off-target effects. Monoclonal antibodies have been widely used in systemic cancer treatments, and their application in intratumoral therapies is gaining traction due to their precision and effectiveness.For instance, GSK’s antibody-drug conjugate, Blenrep (belantamab mafodotin-blmf), was granted FDA approval for the treatment of relapsed or refractory multiple myeloma.

“Amongst Application, the lung cancer segment held a significant share of the market in 2022.”

Based on the application, the market has been categorized into lung cancer, breast, melanoma, prostate cancer, and others. Among them, the lung cancer segment is expected to grow at a higher CAGR in the market due to the high incidence of lung cancer and the increasing adoption of innovative therapies to address this challenging disease. Moreover, standard treatments for lung cancer, such as surgery, chemotherapy, and radiation, can have limitations and significant side effects. Intratumoral therapies aim to address these challenges by targeting the tumor cells while minimizing damage to healthy tissues.For instance, in 2021, Varian Medical Systems, are developing innovative techniques for localized treatment of NSCLC, including intratumoral therapies named Elekta. These techniques aim to target tumours within the lung while minimizing damage to healthy lung tissue.

“Amongst end-user, the hospitals segment held the higher CAGR in the market in 2022.”

Based on the end-user, the market has been categorized into hospitals, radiation therapy center, and cancer research institutes. Among them, the hospital category is to witness higher adoption of intratumoral cancer therapies during the forecast period. The rising incidence of cancer and the growing awareness of cancer among the general population has led to an increased number of patients seeking medical attention and technology at hospitals. In addition, hospitals offer a multidisciplinary approach to bringing together various specialists such as endocrinologists, surgical oncologists, medical oncologists, radiologists, and pathologists to provide comprehensive and personalized care to cancer patients. Moreover, Hospitals often have surgical teams experienced in performing complex thyroid surgeries, including total thyroidectomy and lymph node dissection, which are essential in the management of cancer.

“North America dominated the intratumoral cancer therapies market in 2022.”

The North America intratumoral cancer therapies market is expected to continue to grow in the coming years, driven by the increasing prevalence of cancer and growing awareness of intratumoral cancer therapies among healthcare professionals and the general population, development of advanced imaging techniques and the rise in treatment option.For instance, in 2020, according to American Cancer Society, Cancer is the second most common cause of death in the US, exceeded only by heart disease. around 609,360 deaths from cancer are expected in the US in 2022, which is about 1,670 deaths per day.

Intratumoral cancer therapies Market Report Coverage

Reasons to buy this report:

• The study includes market sizing and forecasting analysis validated by authenticated key industry experts.


• The report presents a quick review of overall industry performance at one glance.


• The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolios, expansion strategies, and recent developments.


• Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.


• The study comprehensively covers the market across different segments.


• Deep dive regional level analysis of the industry.

Customization Options:

The global Intratumoral cancer therapies market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.